Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A(2A) receptor agonist regadenoson

Adenosine A(2A) receptor (A(2A)R) agonists reduce invariant natural killer T (iNKT) cell activation and decrease inflammation in sickle cell disease (SCD) mice. We conducted a phase 1 trial of the A(2A)R agonist regadenoson in adults with SCD. The target dose was 1.44 μg/kg/h. iNKT cell activation w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Field, Joshua J., Lin, Gene, Okam, Maureen M., Majerus, Elaine, Keefer, Jeffrey, Onyekwere, Onyinye, Ross, Ainsley, Campigotto, Federico, Neuberg, Donna, Linden, Joel, Nathan, David G.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2013
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637009/
https://ncbi.nlm.nih.gov/pubmed/23377438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-11-465963
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares